Intrathecal Delivery of CaMKIIα siRNA

2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine) (KN93) and 2-[N-(4-Methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine (KN92) were purchased from Tocris Bioscience (Ellisville, MO). Lidocaine HCl (2%) was from Hospira (Lake Forest, IL). Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). CaMKIIα siRNA (sense, 5′-CACCACCAUUGAGGACGAAdTdT-3′, antisense, 5′-UUCGUCCUCAAUGGUGdTdT-3′) and scrambled RNA duplex control (sense, 5′-AUACGCGUAUUAUACGCGAUUACGAC-3′; antisense, 5′-CGUUAAUCGCGUAUAAUACGCGUAT-3′) were synthesized by Integrated DNA Technologies (Coralville, IW). Lidocaine, KN93, KN92 and RNA duplexes were administered intrathecally (i.t.) in a volume of 5 μL by percutaneous puncture through the L5–L6 intervertebral space.^{26 (link),32 (link)} The RNAs were mixed with a transfection reagent i-Fect (Neuromics, Minneapolis, MN) at a ratio of 1:5 (w/v).^{7 (link)}